CluePoints, the premier provider of risk-based study execution (RBx) and risk-based quality management (RBQM) software for clinical trials, has won the Best Contract Research Organization (CRO): Specialist Providers category at Citeline’s 2023 SCRIP Awards.
The award, presented at The Dorchester in London, on Thursday 16 November, was made in recognition of CluePoints’ innovative solutions, its high-quality relationships with partners and clients, and its commitment to advancing the sector’s knowledge and expertise in RBQM.
The category, for CROs that provide niche services, was judged on achievements made between June 2022 and June 2023. During that time, CluePoints
- organised and sponsored its annual RBQMLive conference, which brought some of the world’s leading RBQM voices together to discuss how to adopt and implement the efficiency saving, safety enhancing approach to clinical trial design and delivery
- partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) on a global survey of more than 125 pharma, biopharma and CROs on current RBQM adoption patterns
- continued working with the FDA through a co-operative research and development agreement (CRADA), to develop a data-driven approach to site inspection, prioritisation and selection
- launched a machine learning (ML) algorithm to streamline medical coding and a deep learning (DL) model to automatically identify discrepancies and anomalies in adverse event and medication data with up to 96% precision.
François Torche, cofounder and Chief Product and Technology Officer of CluePoints, commented: “We are thrilled that our work to further the adoption of RBQM across the industry, and the high-quality innovative solutions and services we provide our customers, has been recognised by the esteemed Scrip Awards team."
"Winning this award really is an honour, especially when considering the amazing companies we were shortlisted alongside."
“I would like to thank all the CluePoints staff who have worked tirelessly to make the organisation what it is today. We will continue our efforts to lead the industry in its RBQM adoption and innovation through our education offerings, our partnerships, and our pioneering technology.”
